Here are five notes:
1. Tekmira Pharmaceuticals has shelved the drug and has opted to focus developing hepatitis B virus treatments.
2. The company will reevaluate its contract with U.S. Department of Defense in light of the TKM-Ebola suspension.
3. Tekmira’s press release comes nearly a month after phase 2 trials results in Sierra Leona revealed the drug is unlikely to be beneficial for humans.
4. Some patients exhibited flu-like symptoms in the first phase of the trial.
5. The U.S. Food and Drug Administration put a clinical hold on the drug to analyze the multiple-ascending-dose part of the trial. The FDA later changed its action to allow repeat dosing at a lower dose, which allowed the trial to resume.
More articles on infection control & quality:
68% of visits for acute respiratory infections result in an antibiotic prescription: 6 things to know
Threat of West Nile in New York City: 5 facts to note
Cause for concern: 10 notes on the measles outbreak
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
